• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Litifilimab associated with reduced disease severity in patients with cutaneous lupus erythematosus

byAndrew LeeandKiera Liblik
August 8, 2022
in Chronic Disease, Rheumatology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Litifilimab significantly decreased cutaneous lupus erythematosus (CLE) disease area and severity index scale (CLASI-A) after 16 weeks of treatment.

2. Litifilimab may increase the risk of adverse reactions including upper respiratory tract infection, influenza, herpes zoster, viral rash, and systemic viral infections.

Evidence Rating Level: 1 (Excellent)

Study Rundown: CLE is an autoimmune disease that can result in permanent damage, disfigurement, and decreased quality of life. It is further associated with mental health implications such as depression, anxiety, and fatigue. Litifilimab is currently being investigated as a possible therapeutic agent. It is an IgG1 monoclonal antibody that engages blood dendritic cell antigen 2. This inhibits type I interferons, inflammatory cytokines, and chemokines, targeting the pathophysiology of CLE. The present study compared litifilimab to a placebo control in a group of patients with CLE. The study group showed a significant dose-response relationship in the reduction of their CLE disease area and CLASI-A score after 16 weeks of treatment. A limitation of this study includes concomitant treatment of CLE with other medications, which could affect the effect size of the treatment group.

Click to read the study in NEJM

Relevant Reading: Trial of Anifrolumab in active systemic lupus erythematosus

In-Depth [randomized control trial]: This phase two randomized control trial evaluated the efficacy of litifilimab in reducing CLASI-A after 16 weeks of treatment. Adults 18 to 75 years of age were eligible if they had a histologically confirmed diagnosis of CLE or received biopsy screening for the study. Participants had to have a CLASI-A score of eight or greater at the beginning of the study. The least-squares mean percent changes in CLASI-A scores from baseline to the end of the trial (week 16) were -14.5+/-6.4 for the placebo group, -38.8+/-7.5 for 50mg litifilimab group, -47.9+/-7.5 for 150mg litifilimab group, and -42.5+/-5.5 for 250mg litifilimab group. Negative values represent a clinical improvement from baseline. In comparison to placebo, the CLASI-A score change from baseline to week 16 was -24.3% for 50 mg litifilimab group (95% confidence interval [CI], -43.7 to -4.9), -33.4% for 150mg litifilimab group (95% CI, -52.7 to -14.1), and -28% for 450mg litifilimab group (95% CI, -44.6 to -11.4). The secondary end-point was CLASI-50, a decrease of 50% from the baseline CLASI-A score. The least mean squared difference between treatment group and placebo were as follows: 15.8% for 50mg group (95% CI, -7.2 to 38.8), 21.2% for 150mg group (95% CI, -2.8 to 45.2), and 23.3 for 450mg group (95%CI, 2.9 to 43.6). Litifilimab is a potential treatment for CLE, however larger and longer trials are necessary to determine its true efficacy and safety.

RELATED REPORTS

Epstein-Barr viral load monitoring reduces risk of post-liver transplant lymphoproliferative disease

Catheter ablation reduces rates of persistent atrial fibrillation and atrial tachyarrhythmia

Deep intronic FGF14 repeat expansion associated with late-onset cerebella ataxia

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: chronic diseasecutaneous lupus erythematosusIgG1 monoclonal antibodyLitifilimabLupusrheumatology
Previous Post

Shorter time to surgical repair of macula-off retinal detachment may improve final visual acuity

Next Post

Gout flares associated with a transient increase in subsequent risk of cardiovascular events

RelatedReports

Resection of colorectal liver metastases may improve cost and longevity
Chronic Disease

Epstein-Barr viral load monitoring reduces risk of post-liver transplant lymphoproliferative disease

January 30, 2023
β-blockers linked to improved survival in preserved ejection fraction heart failure
Cardiology

Catheter ablation reduces rates of persistent atrial fibrillation and atrial tachyarrhythmia

January 27, 2023
Brain lesions on MRI linked with subsequent increased stroke risk
Chronic Disease

Deep intronic FGF14 repeat expansion associated with late-onset cerebella ataxia

January 27, 2023
2 Minute Medicine Rewind May 20, 2019
Chronic Disease

Chronic obstructive pulmonary disease associated with worse postoperative outcomes

January 26, 2023
Next Post
Increased diabetes risk observed in gout patients

Gout flares associated with a transient increase in subsequent risk of cardiovascular events

Implementation of pneumococcal vaccine programs linked to decreased antibiotic prescription

Management of uncomplicated urinary tract infections amongst women in the United States Military Health System highly concordant with guidelines

Carbon nanotubes ameliorate methamphetamine addiction in mice [PreClinical]

Methamphetamine use associated with cardiovascular disease in hospitalized patients

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Higher rate of sudden infant death syndrome (SIDS) amongst siblings of prior SIDS victims
  • #VisualAbstract: Extracorporeal and conventional cardiopulmonary resuscitation have similar effects on neurologic outcome in patients with refractory out-of-hospital cardiac arrest
  • Rocatinlimab may be effective in the treatment of moderate-to-severe atopic dermatitis
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options